Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marie Fechtenbaum

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
British Journal of Hospital Medicine (London, England : 2005)|August 12, 2014
Biologics in rheumatoid arthritis: where are we going?Marie Fechtenbaum, Jackie L Nam, Paul Emery
Expert Opinion on Biological Therapy|March 25, 2014
Certolizumab pegol in rheumatoid arthritis: current updateMarie Fechtenbaum, Md Yuzaiful Md Yusof, Paul Emery
Joint Bone Spine|July 23, 2014
Toxidermia under treatment with tocilizumab for rheumatoid arthritisMarie Fechtenbaum, Christopher Banse, Pauline Boyard-Lasselin, et al.
Joint Bone Spine|October 14, 2019
Baseline MRI inflammation is not a determinant of 5-year bone mineral density loss in patients with early spondyloarthritisMarie Fechtenbaum, Anna Molto, Christian Roux, et al.
Genes and Immunity|September 5, 2018
MICA and NKG2D variants as risk factors in spondyloarthritis: a case-control studyMarie Fechtenbaum, Judith Desoutter, Gauthier Delvallez, et al.
Pharmacology|April 27, 2016
Decrease of Tocilizumab Dose in Patients with Rheumatoid Arthritis: A Pilot StudyMarie Fechtenbaum, Pauline Lasselin-Boyard, Sarah Salomon, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
British Journal of Hospital Medicine (London, England : 2005)|August 12, 2014
Biologics in rheumatoid arthritis: where are we going?Marie Fechtenbaum, Jackie L Nam, Paul Emery
Expert Opinion on Biological Therapy|March 25, 2014
Certolizumab pegol in rheumatoid arthritis: current updateMarie Fechtenbaum, Md Yuzaiful Md Yusof, Paul Emery
Joint Bone Spine|July 23, 2014
Toxidermia under treatment with tocilizumab for rheumatoid arthritisMarie Fechtenbaum, Christopher Banse, Pauline Boyard-Lasselin, et al.
Joint Bone Spine|October 14, 2019
Baseline MRI inflammation is not a determinant of 5-year bone mineral density loss in patients with early spondyloarthritisMarie Fechtenbaum, Anna Molto, Christian Roux, et al.
Genes and Immunity|September 5, 2018
MICA and NKG2D variants as risk factors in spondyloarthritis: a case-control studyMarie Fechtenbaum, Judith Desoutter, Gauthier Delvallez, et al.
Pharmacology|April 27, 2016
Decrease of Tocilizumab Dose in Patients with Rheumatoid Arthritis: A Pilot StudyMarie Fechtenbaum, Pauline Lasselin-Boyard, Sarah Salomon, et al.
Pageof 1